TG Therapeutics (TGTX) is a publicly owned bio-pharmaceutical company that focuses on the procurement, development and commercialisation of innovative treatments for B-cell malignancies and autoimmune diseases. The company was founded in 1933 by Michael Sean Weiss and Laurence H. Shaw and is currently headquartered in New York City, New York. The Implied Volatility (IV) is currently at 136%, showing a whopping increase by 63% from 73%. The ATM straddle premium % is at 31.65%, having risen from 17.29% with a growth of 14.36%. https://www.raltin.com/b/tg-therape...-goes-through-roof-and-52-week-high-136-cm457